Alexa Fluor® 700 anti-mouse Ly-6C Antibody
- 产品名称：
- Alexa Fluor® 700 anti-mouse Ly-6C Antibody
- 产品类别：
- 抗体
- 产品编号：
- 128023
- 产品应用：
- 128023
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- L3 cloned CTL cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 700 under optimal conditions.
- Concentration
- 0.5 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is highly recommended that the reagent be titrated for optimal performance for each application.
* Alexa Fluor? 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor? 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.
Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.
View full statement regarding label licenses - Excitation Laser
- Red Laser (633 nm)
- Application Notes
Clone HK1.4 does not block the binding of clone RB6-8C58.
Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.
- Application References
(PubMed link indicates BioLegend citation) -
- Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
- Herold KC, et al. 1990. Diabetes 39:815. (Activ)
- Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
- Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
- Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
- Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
- Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
- Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
- Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
- Product Citations
-
- Lee JH, et al. 2022. EBioMedicine. 77:103903. PubMed
- Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
- Denk D, et al. 2022. Immunity. 55:2059. PubMed
- Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
- Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
- Kolawole A, et al. 2015. J Virol. 90: 1499-1506. PubMed
- Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
- Minutti CM, et al. 2019. Immunity. 50:645. PubMed
- Lindborg JA et al. 2017. The Journal of Neuroscience. 37(43):10258-10277 . PubMed
- Parrish KE, et al. 2021. Biopharm Drug Dispos. 42:137. PubMed
- Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
- Zhang X, et al. 2020. Elife. 9:00. PubMed
- Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
- Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed
- Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
- Deng M, et al. 2020. Nat Commun. 11:2193. PubMed
- Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
- Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
- Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
- Ritzel RM, et al. 2021. Glia. 69:746. PubMed
- Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
- Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
- Nacer A, et al. 2014. PLoS Pathog. 10:1004528. PubMed
- Velázquez F, et al. 2016. J Immunol. 196: 1305 - 1316. PubMed
- Chhatbar C et al. 2018. Cell reports. 25(1):118-129 . PubMed
- Issah Y, et al. 2021. Elife. 10:. PubMed
- Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
- T?htinen S, et al. 2022. Nat Immunol. 23:532. PubMed
- Ortega-Molina A, et al. 2021. Cell Reports. 36(2):109372. PubMed
- Jin J, et al. 2020. Cell Reports. 30(12):4124-4136. PubMed
- Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
- Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
- Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
- Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
- Buschor S, et al. 2017. PLoS Pathogens. 13(6):e1006476. PubMed
- RRID
- AB_10640119 (BioLegend Cat. No. 128023) AB_10643270 (BioLegend Cat. No. 128024)
- Structure
- 14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
- Distribution
-
Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.
- Cell Type
- Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.
- Gene ID
- 17067 View all products for this Gene ID
- UniProt
- View information about Ly-6C on UniProt.org
